Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer episode artwork

EPISODE · Mar 31, 2017 · 55 MIN

Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

from AUAUniversity · host American Urological Association

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck

NOW PLAYING

Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer

0:00 55:09

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AUAUniversity?

This episode is 55 minutes long.

When was this AUAUniversity episode published?

This episode was published on March 31, 2017.

What is this episode about?

The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events....

Can I download this AUAUniversity episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!